The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Equity stake in Bupa Arabia
Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia
LCH.Clearnet SA
Advised LCH.Clearnet Group Limited, a leading multi-asset class European clearing house, on a sale of LCH.Clearnet SA, its French-regulated operating subsidiary, to Euronext N.V. that was ultimately terminated
Host Europe Group
Advised GoDaddy, the largest domain name registrar worldwide and a leading web hosting provider, on its acquisition of Host Europe Group, the largest privately owned web services provider in Europe
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
US rights to Toprol-XL (AstraZeneca)
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
US rights to 37 approved and 5 pipeline generic products
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
Equinix Data Center Assets
Advised Digital Realty Trust, the world's largest wholesale colocation services and data center solutions provider, on its acquisition of a portfolio of eight carrier-neutral European data centers from Equinix
Frieze Events Ltd. / Frieze Publishing Ltd.
Advised Frieze, the premier art events and media company, on its strategic investment and partnership with WME IMG Global
Wireless Infrastructure Group
Advised 3i Infrastructure plc, a leading UK listed investor in infrastructure businesses and assets, on its acquisition of a 36% economic interest in Wireless Infrastructure Group, the UK’s 2nd largest independent telecommunications tower company
Air Warfare Destroyer Reform Strategy
Advised the Commonwealth Government of Australia as represented by the Department of Finance in relation to the Air Warfare Destroyer Reform Strategy
Allied Healthcare
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
COOEC Fluor Heavy Industries Co., Ltd.
Advised Fluor Corporation on its $489 million investment for a 49% interest in a joint venture with Offshore Oil Engineering Co., Ltd. (COOEC) to own, operate and manage the Zhuhai Fabrication Yard in China’s Guangdong province
Victorian Thoroughbred Racing Media Rights
Advised Tabcorp Holdings Limited (“Tabcorp”), a leading diversified Australian entertainment group with wagering, gaming, racing media and Keno operations, on reaching agreement on a long-term deal for domestic broadcast, digital and international media rights for Victorian thoroughbred racing content
Allergan Generics
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
Gala Coral Limited
Advised Ladbrokes plc, a leading UK betting and gaming company, on the recommended all-share merger with certain businesses of Gala Coral Limited, including Coral Retail, Eurobet Retail and Gala Coral Online
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
Scholastic Corporation’s Educational Technology and Services business
Advised Scholastic Corporation, a children’s publishing and education company, on the sale of its Educational Technology and Services business to Houghton Mifflin Harcourt Company, an educational and trade publisher
Refinancing of syndicated bank debt facilities
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
John Laing plc
Advised Henderson Equity Partners on the initial public offering of John Laing plc, a leading originator, active investor and manager of international infrastructure projects
Chandler Macleod Group Limited
Advised Recruit Holdings Co.,Ltd, the leading global staffing services company in Japan, on the acquisition of Chandler Macleod Group Limited, a major general recruitment company
Peoplebank Holdings PTY LTD
Advised Recruit Holdings Co.,Ltd, the leading global staffing services company in Japan, on the acquisition of Peoplebank Holdings PTY LTD, Australasia’s leading IT&T recruitment company
NYK Ports LLC
Advised NYK Ports LLC, a leading port operating and stevedoring company, on the sale of a 49% stake to Macquarie Infrastructure Partners, a leading Australian infrastructure fund